» Articles » PMID: 33609052

Effectiveness of Fidaxomicin Versus Oral Vancomycin in the Treatment of Recurrent Clostridioides Difficile

Overview
Specialties Pharmacology
Pharmacy
Date 2021 Feb 20
PMID 33609052
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

What Is Known And Objective: The 2017 IDSA/SHEA Clinical Practice Guidelines for Clostridioides difficile infection (CDI) recommend treating recurrent episodes with fidaxomicin or oral vancomycin, but there is little evidence to support one strategy over another, particularly beyond the first recurrence. The aim of this study was to compare clinical outcomes in patients with recurrent CDI treated with vancomycin vs. fidaxomicin.

Methods: This retrospective study evaluated inpatients with recurrent CDI treated with vancomycin or fidaxomicin between 1 January 2013 and 1 May 2019. The primary outcome was CDI recurrence. Secondary outcomes included re-infection, treatment failure, infection-related length of stay (IRLOS) and in-hospital all-cause mortality (IHACM). The Wilcoxon rank-sum test, Pearson's chi-square test or Fisher's exact test was utilized, as appropriate. A multivariable logistic regression (MLR) model was used to estimate the adjusted odds ratio and 95% confidence interval assessing recurrence while adjusting for confounding variables. A survival analysis was also conducted.

Results: 135 patients met the inclusion criteria (35 fidaxomicin vs. 100 vancomycin). There was no difference in CDI recurrence [7 (20%) fidaxomicin vs. 11 (11%) vancomycin, p = 0.18]; this persisted in the MLR model (OR: 0.85 [95% CI 0.27-2.7]) and survival analysis (p = 0.1954). Additionally, there was no difference in re-infection rate (p = 0.73), treatment failure (p = 0.13), IRLOS (p = 0.19) or IHACM (p = 0.65).

What Is New And Conclusion: This represents the first analysis of CDI recurrence that included patients with >2 prior episodes of CDI. The study found no difference in additional recurrences when patients were treated with oral vancomycin vs fidaxomicin for recurrent CDI. However, the current study is limited by the small sample size available for inclusion. Prospective randomized studies with larger sample sizes are needed to confirm this study's conclusions.

Citing Articles

Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review.

Li Q, Obi E, Marciniak A, Newman R, Whittle I, Kufakwaro J Medicine (Baltimore). 2025; 103(52):e39219.

PMID: 39969373 PMC: 11688082. DOI: 10.1097/MD.0000000000039219.


Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy under enforcement discretion for the prevention of recurrent infection.

Knapple W, Yoho D, Sheh A, Thul J, Feuerstadt P Therap Adv Gastroenterol. 2024; 17:17562848241239547.

PMID: 38529070 PMC: 10962041. DOI: 10.1177/17562848241239547.


Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) Administered Under Enforcement Discretion to Patients With Infection.

Feuerstadt P, Harvey A, Yoho D, Garcia-Diaz J, Knapple W, Bancke L Open Forum Infect Dis. 2023; 10(5):ofad171.

PMID: 37256213 PMC: 10225279. DOI: 10.1093/ofid/ofad171.


Treatment of Clostridioides difficile infection: from guidelines to clinical practice.

Merino E, Salavert M Rev Esp Quimioter. 2022; 35 Suppl 3:97-101.

PMID: 36285868 PMC: 9717447. DOI: 10.37201/req/s03.21.2022.


Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Infection and Associated Clinical Outcomes.

Dubberke E, Puckett J, Obi E, Kamal-Bahl S, Desai K, Stuart B Open Forum Infect Dis. 2022; 9(10):ofac435.

PMID: 36267250 PMC: 9578155. DOI: 10.1093/ofid/ofac435.